Chinese Atrial Fibrillation Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Atrial Fibrillation (AF). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This prospective, observational cohort study aims to establish a long-term registry of adult patients with atrial fibrillation (AF) in China to comprehensively characterize patient profiles and evaluate real-world management and outcomes over time. The objectives of the study are to: * Describe the demographic, clinical, and treatment characteristics of AF patients across different stages of disease progression. * Assess the effectiveness and safety of various AF treatment strategies, including oral anticoagulation, catheter ablation, and left atrial appendage closure, in routine clinical practice. * Identify patient- and treatment-related factors that influence therapeutic outcomes. * Explore the role of advanced technologies and artificial intelligence in improving procedural performance, risk stratification, and clinical decision-making in AF care. Participants will undergo standardized baseline evaluation and longitudinal follow-up to collect data on heart rhythm monitoring, treatment exposures, healthcare utilization, clinical events, and patient-reported outcomes. This cohort will generate real-world evidence to inform personalized and evidence-based management of AF.
Detailed description
This prospective, multicenter observational registry aims to collect standardized clinical data on adults with atrial fibrillation (AF) across over 30 hospitals in China. The study reflects real-world clinical practice and does not interfere with treatment decisions.
Baseline and follow-up data will be collected using standardized forms, including demographics, medical history, cardiovascular risk factors, laboratory and imaging results, medication use, and-when applicable-procedural details for catheter ablation, such as energy source and complications.
Follow-up will be conducted at 1, 2, 3, and 6 months after enrollment, and every 6 months thereafter. Data include ECG monitoring, medication updates, hospitalizations, adverse events (e.g., stroke, bleeding, cardiovascular death), and healthcare utilization. Quality of life, cognitive, and psychological assessments may also be collected.
All treatments are determined by physicians as part of usual care. The registry provides internal feedback on potential treatment issues and generates periodic, anonymized summaries for participating centers.
The study aims to inform clinical practice and support real-world evidence generation to improve AF management in China.
Primary outcome measures
- All-cause death [Time frame: 10 years]
Secondary outcome measures (9)
- Ischemic Stroke [Time frame: 5 years]
- Hemorrhagic Stroke [Time frame: 5 years]
- Transient ischemic attack (TIA) [Time frame: 5 years]
- Cardiovascular Death [Time frame: 5 years]
- Cardiovascular Hospitalization [Time frame: 5 years]
- Systemic Embolism [Time frame: 5 years]
- Thromboembolic Death [Time frame: 5 years]
- Major Bleeding [Time frame: 5 years]
- Clinically Relevant Non-Major Bleeding (CRNMB) [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years;
- Documented atrial fibrillation episode lasting >30 seconds confirmed by electrocardiogram (ECG), Holter monitor, implantable cardiac monitor, or wearable ECG device
- Signed informed consent and willingness to participate in follow-up
Exclusion criteria
- Atrial fibrillation due to a reversible cause (e.g., transient secondary AF)
- Presence of comorbid conditions associated with an expected life expectancy of less than 1 year
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 2 centers
- Beijing Anzhen Hospital — Beijing
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou
Publications
- Ren L, Peng X, Li M, He L, Zhou N, Liu X, Zuo S, Dong J, Ma C, Guo X. Association of left ventricular geometry with outcomes and treatment response in atrial fibrillation and heart failure with preserved ejection fraction. Front Med (Lausanne). 2026 May 4;13:1824509. doi: 10.3389/fmed.2026.1824509. eCollection 2026. PMID 42158122
Identifiers
NCT: NCT06987825 · KS2025087